DonCorleone77 Posted - 5 hours ago

$ZLAB $PFE Zai Lab, Pfizer enter collaboration for Xacduro Zai Lab (ZLAB) and Pfizer (PFE) announced a strategic collaboration for the novel antibacterial drug Xacduro in mainland China. Pfizer's affiliated companies will be exclusively authorized to undertake and perform certain commercialization activities for Xacduro in mainland China. Through this collaboration, Zai Lab will leverage the commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to help accelerate access to this important therapy for patients in need in mainland China. The period of collaboration is for the imported product through November 2028, subject to early termination or extension.

frontiere Posted - 6 hours ago

Interesting $ZLAB Zai Lab strat partnering $PFE Pfizer for China Abx dev — relevant somewhat to ANTX SPRO INSM etc https://www.businesswire.com/news/home/20241121825806/en/Zai-Lab-and-Pfizer-Announce-Strategic-Collaboration-on-the-Novel-Antibacterial-Drug-XACDURO%C2%AE-Sulbactam-Durlobactam

buylowandwait Posted - 2 days ago

$ZLAB I am holding different opinion about this shit co since last week’s offering at 25. You have tons of assets already, if you can’t do well with 700M+, adding 200M is not going to change anything …

Pika_Capital Posted - 2 days ago

$ZLAB they got almost $1B in cash after recent offering, trending towards profitability. Keep selling idiots at $25 🤡

MaverikIT Posted - 6 days ago

@IsabellaDC @net0trader $ZLAB +1.98 $PLTR - going to Nazdog $AOSL - trying

OpenOutcrier Posted - 6 days ago

$ZLAB (+5.6% pre) Zai Lab Announces Pricing of Public Offering of American Depositary Shares - SI https://ooc.bz/l/48281

briefingcom Posted - 6 days ago

Gapping up: $DESP +13.3% $RCAT +12.9% $CWCO +7.2% $EVO +7.2% $ZLAB +6%

DonCorleone77 Posted - 6 days ago

$ZLAB Zai Lab 7.84M share Secondary priced at $25.50 Goldman Sachs, Jefferies and Leerink acted as joint book running managers for the offering.

Spartrap Posted - 6 days ago

$ZLAB offering priced at $25.5

doubleyou2 Posted - 6 days ago

$ZLAB That's why I hate those offerings, and surely because they don't really need the cash here. They always kill the momentum. Zailabs stockprice was nicely recovering from the lows. Done for today.

BioTechChap Posted - 6 days ago

$ZLAB $25.5

SodApOp_PIMPski Posted - 6 days ago

$ZLAB gap officially filled... added back half here🎯🎯🎯

JD918 Posted - 6 days ago

$ZLAB normal volume with an exaggerated drop, I'm in for a quick bounce.

BioTechChap Posted - 6 days ago

$ZLAB Janus Henderson have been loading, + today's SC 13G filing. Dilution always sucks, but we're in good company.

OpenOutcrier Posted - 1 week ago

$ZLAB (-6.1% pre) Zai Lab Announces Proposed Public Offering of American Depositary Shares - BW https://ooc.bz/l/48101

Tdorsey1776 Posted - 1 week ago

$ZLAB Why? Very fishy offering.

doubleyou2 Posted - 1 week ago

$ZLAB Can anyone find in the PR or in that 424B5 what the offering price is in $ ? I can't immediatly.

Pika_Capital Posted - 1 week ago

$ZLAB are you serious. Do You really need those $200m with $700m cash pile? Omg what a f idiots, we just recovered to $30

buylowandwait Posted - 1 week ago

$ZLAB What a shit show is this? Out of all the outcomes, I've never expected this company to sell shares to raise more cash ! Looks like 700M+ cash without debt is not enough for this shit Co, it wants more so they can waste away...

SodApOp_PIMPski Posted - 1 week ago

$ZLAB 🎯

SodApOp_PIMPski Posted - 1 week ago

$ZLAB yikes

DonCorleone77 Posted - 1 week ago

$ZLAB Zai Lab announces $200M American depositary shares offering Zai Lab Limited announced that it has commenced an underwritten public offering of $200M of American depositary shares, ADSs, each representing ten ordinary shares of the company with a par value of $0.000006 per share. All ADSs will be offered by Zai Lab. Zai Lab intends to use the net proceeds from this offering for general corporate purposes. Goldman Sachs, Jefferies and Leerink Partners are acting as joint book-running managers for the offering.

BioTechChap Posted - 1 week ago

$ZLAB Q3 R&D expense included one-off KarXT upfront and milestone fees= 22M. Company is on right path for break-even in 2025

Pika_Capital Posted - 1 week ago

$ZLAB good numbers. Cash burn decreased. Absolutely no reason to sell at these levels with so many drugs coming to the market within next 2 years

SodApOp_PIMPski Posted - 1 week ago

$ZLAB first gap filled🎯

SodApOp_PIMPski Posted - 1 week ago

$ZLAB 26 gap gonna fill

DonCorleone77 Posted - 1 week ago

$ZLAB Zai Lab reports Q3 EPS (42c), consensus (78c) Reports Q3 revenue $101.8M, consensus $102.24M. Cash and cash equivalents totaled $716.1M as of September 30 vs.$730.0M as of June 30. "In Q3, we delivered strong commercial results, maintained financial discipline, and continued to advance our global pipeline of innovative medicines," said CEO Samantha Du. "The launch of Vyvgart has been a great success, and we are well-positioned to support the ongoing needs of many patients living with generalized myasthenia gravis. Our late-stage pipeline is progressing well. The China bridging study of KarXT for schizophrenia had positive results for all study endpoints, and we expect a China submission in early 2025...We believe we are on track to drive substantial value for our business over the next few years." "Our net product revenues in Q3 grew 47% y-o-y, driven by the continued strong uptake of Vyvgart," said COO Josh Smiley. "Vyvgart in gMG, is on track to be a blockbuster launch in its first year on China's National Reimbursement Drug List...we expect to launch the subcutaneous formulation of Vyvgart for gMG and chronic inflammatory demyelinating polyneuropathy in Q4. Our late-stage programs including bemarituzumab for gastric cancer and KarXT for schizophrenia present high potential opportunities that will further drive growth. Meanwhile, we had significant improvement in net loss, driven by our continued efforts to improve efficiency and exercise financial discipline..."

ChessGM Posted - 1 week ago

$ZLAB Heads up alert! Upcoming earnings on Tuesday, 11/12/2024 for $ZLAB Bullish (8.2) Zai Lab Limited (ZLAB) is experiencing a strong upward trajectory fueled by recent positive developments in its clinical trials and robust investor interest. The company reported impressive outcomes from its Phase 3 trials for its schizophrenia treatment, KarXT, which achieved its primary endpoint with a statistically significant reduction in the Positive and Negative Syndrome Scale (PANSS) total score. This positive momentum is further supported by strong performance from its investigational drug ZL-1310 for small cell lung cancer, which has shown promising response rates and a favorable safety profile. Financially, ZLAB’s growth metrics are noteworthy; analysts project a solid revenue forecast with a potential P/E ratio that places it favorably against industry peers. The expected earnings per share (EPS) growth appears favorable, especially considering Zai Lab’s aggressive R&D strategy in a high-growth sector. The company’s stock has surged significantly, hitting a 16-month high, reflecting investor confidence in its ongoing clinical programs and strategic positioning within the biotech space. Upcoming earnings reports are critical for Zai Lab as it approaches the announcement of its third-quarter financial results on November 12, 2024. Expectations are high, with analysts estimating continued positive momentum in revenue growth and EPS. Historically, ZLAB has demonstrated strong performance in earnings calls, often exceeding market expectations, which could further support its valuation. The upcoming conference call will likely address recent corporate updates and provide insights into the strategic direction of its pipeline. Should the company deliver results that align with or surpass analyst consensus estimates, it could solidify its bullish outlook and attract additional investment, reinforcing its position in the competitive biotech landscape. - Funds were net buyers of $ZLAB during the previous reporting quarter. - Top 1 funds with large holdings in $ZLAB: * Viking Global Investors LP $35MM. New position. CGMFundRank: 79%, Fund Website: www.vikingglobal.com - Last 10 days performance: -7% - Last 30 days performance: 22% - Last 90 days performance: 86% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.

Spartrap Posted - 1 week ago

$ZLAB ER Tuesday, PM

SodApOp_PIMPski Posted - 10/30/24

$ZLAB 29 first gap, if that doesn't hold... 26.50 next